Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib in Hepatocellular Carcinoma
NCT01246986Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2011
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of galunisertib in hepatocellular carcinoma (HCC) (7 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS) up to 83 months, Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS) up to 83 months and 1 more. Started Mar 2011; status: completed.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01246986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01246986.